CSL stacks up $4.5B in chips — with a $200M ante — to wager on the next-gen mRNA wave
Australian pharma giant CSL is making a late bid for mRNA glory, and they’ve lined up one of the also-ran US Covid-19 biotechs touting their own particular tech twist to partner with.
CSL Seqirus, the big vaccines arm of the global player, is shelling out $200 million in cash and putting up another $4.3 billion in milestones — including a hefty $1.3 billion for development goals — to ally itself with Arcturus Therapeutics. Joe Payne’s San Diego-based biotech — where Payne had to mount a counter-coup to wrest back control of the company from some rebellious board members in 2018 — is just coming off a $63 million BARDA contract, where they’re putting their mRNA tech to work on the flu.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.